Emergent BioSolutions Inc

The stock is entrenched in a Stage 4 decline, trading sideways below its major moving averages with persistent lower highs and lower lows. Medium-term bias remains bearish, permitting only sell-side engagement, while short-term conditions lack a clear timing edge. Execution is deferred until price rallies into resistance around the 9/21 EMA cluster or the upper consolidation boundary, where rejection at EMAs can be probed for trade entries.

• ↑Q4’25 revenue $743M and adj. EBITDA $205M (+12% YoY)
• ↑Secured $52.7M government contracts; international sales 34% of MCM revenue
• ↓2026 lacks repeat of $60M intl order, exposing contract volatility